On November 7, 2024, amended the credit agreement with OrbiMed in a mutually beneficial arrangement, forgoing access to an additional $50 million in funding in exchange for removal of the 12-month ...

Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural's IL-18 variants, reinforcing ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, off-the-shelf c ...

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

Richard DiIorio, Chief Executive Officer of InfuSystem, said, "Our third quarter financial results reflect the forecasted acceleration in our business in the second half of the year. We saw ...

About Aulisa Medical Head-quartered in Silicon Valley, Aulisa® Medical is a leading medical technology company founded by serial medical technologies entrepreneur ... The Phase 1b/2 study FUMANBA-1 ...

Libra Industries, a privately-held systems integration and electronics manufacturing services (EMS) provider, is excited to announce the expansion of its state-of-the-art Powder Coat paint line at its ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a do ...

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...